Frontier Medicines raises $80M, enters clinic and eyes potential IPO in Q4 or early 2025

Frontier Medicines, a bicoastal biotech creating covalent small molecules, has secured $80 million in Series C funds and dosed the first patient in its initial clinical trial as it looks to create a next-generation KRAS treatment behind Amgen and Bristol Myers-acquired Mirati.

The South San Francisco and…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks